my country's hormone API exports have entered a normal trade track
Introduction: Hormone APIs are traditional export commodities in my country with high market concentration. However, in recent years, affected by the European debt crisis and rising domestic factor costs, its exports have been hovering at a low level. In 2014, the average export price dropped by 17.97%, the lowest in history.
According to the statistics of China Customs, in 2014, the export value of my country's hormone APIs increased by 52.99% year-on-year, achieving the largest increase since the European debt crisis. It can be seen that with the continuous recovery of major European economies, my country's hormone API exports have gradually into the normal trade track.
In recent years, due to the increase in domestic clinical applications and the development of the aquaculture industry, the production of hormone-based APIs has increased year by year, and the industry has developed rapidly.
Volume and price go their separate ways
In 2014, the export volume of hormone APIs in my country increased by 86.5% year-on-year, while the average export price decreased by 17.97% year-on-year. Therefore, the analysis believes that although the European economic recovery has brought benefits to my country's pharmaceutical export trade, the capital chain of foreign buyers is still tight. , so that the profits of my country's export enterprises are squeezed.
In 2014, my country's hormone APIs were exported to 112 countries and regions, of which: the export value to Asia increased by 46.43% year-on-year; the export value to Europe increased by 78.67% year-on-year. The above two continents are the main export markets of my country's hormone APIs, accounting for 80.12%. In 2014, my country's top 10 export trading partners were India, the United States, Italy, the Netherlands, Belgium, Germany, Switzerland, the United Kingdom, Spain, and Brazil. The 10 countries accounted for 71.24% of my country's total exports of hormone APIs.
In 2014, there were 510 enterprises engaged in the export trade of hormone APIs in my country. Among them, there are 393 private enterprises, accounting for 47.7% of the export value, accounting for about half of my country's hormone API exports, and 49 foreign-funded enterprises, accounting for 24.91% of the export value. Tianjin Tianfa Pharmaceutical Import & Export Corporation, Changzhou Jiaerke Pharmaceutical, Zhejiang Xianju Pharmaceutical, Zhejiang Xianju Junye Pharmaceutical, Zhejiang Tiantai Orient Pharmaceutical, Henan Lihua Pharmaceutical, Hunan Steroid Chemical The company, Zhejiang Xianju Xianle Pharmaceutical, Jiangxi Hongyuan Pharmaceutical Raw Materials Company, and Tianjin Jinjin Pharmaceutical occupy the top 10 export enterprises of hormone raw materials in my country. Zhejiang, Tianjin, and Jiangsu are among the top three export provinces and cities, accounting for 62.09% of the export value, reflecting a very high market concentration.
Continuation of the status of a major exporting country
In a broad sense, hormone drugs are drugs that use human or animal hormones (including organic substances with the same structure and principle of action as hormones) as active ingredients. Usually, the "hormone drugs" in the mouth of doctors generally refer to adrenal glucocorticoid drugs when there is no special designation. For other hormone drugs, their classification names are often used, such as androgen, insulin, growth hormone, etc.
In 2014, the top 10 export varieties of hormone APIs in my country were: other estrogen (steroid) hormones and progesterone; cortisone, hydrocortisone, dehydrocortisone and dehydrocortisol; other corticosteroids Halogenated derivatives of steroid hormones; other steroid hormones and their derivatives and structural analogs; dexamethasone; gonadotropins; danazol; dehydrochloromethyltestosterone (including andro-1-ene-3,17 -Diketones, (Δ)androstenediol, pratestosterone, deoxymethyltestosterone); mibolone, nandrolone, nobolone, nostebo (including 19-norandrostenediol, 19 - norandrostenedione, noethylandrolone); other hormones and their derivatives and structural analogs.
Hydrocortisone and dexamethasone are still the bulk varieties of hormone API exports in my country, accounting for about 30% of the export value. In 2014, the export volume and price of hydrocortisone decreased by 5.57% and 8.04% respectively; The markets are: Asia, Europe and North America, accounting for 88.82% of the export value. Among the export countries, India, Italy, the United States, Spain and Germany ranked the top 5, accounting for 53.72% of the export value.
The top 5 exporting companies are Tianjin Tianfa Pharmaceutical, Henan Lihua Pharmaceutical, Zhejiang Xianju Pharmaceutical, Tianjin Jinjin Pharmaceutical, and Lijiang Yinghua Biological, accounting for 79.97% of the export value.
The export volume of dexamethasone increased by 9.37%, and the export price decreased by 6.43%; while the export value of Africa and Latin America, which are emerging markets, increased by 67.58% and 31.12% respectively, becoming a highlight of dexamethasone exports in 2014. The top five export countries are all Asian markets, namely India, Indonesia, Malaysia, Singapore, and Pakistan, accounting for 59.07% of the export value.
The top 5 export enterprises are Tianjin Tianfa Pharmaceutical, Zhejiang Xianju Pharmaceutical, Zhejiang Xianju Junye Pharmaceutical, Zhejiang Xianju Xianle Pharmaceutical, and Hengshi Group, accounting for 89.11% of the export value.
my country is a major exporter of hormone APIs and has a dominant position in the international market. It is predicted that in 2015, the weak economic situation of Europe and Japan in the international market will be difficult to change in the short term, and emerging markets and small and medium emerging economies generally perform poorly. The trend of economic differentiation is obvious.
Domestically, the downward pressure on the overall economy has increased, the planting area of the upstream raw material turmeric has decreased, and the environmental protection requirements have increased the cost. All these unfavorable factors have cast a shadow on the recovery and growth of our hormone API exports. The possibility of making profits in the market is already low. Therefore, my country's hormone API business enterprises must change the traditional marketing mode, speed up the industrial transformation, from low-price competition to quality and technology competition, increase the development of high-end products, decompose the competitive pressure of low-end products, and create their own Brand products, strive for more international market share, improve the export efficiency of my country's hormone API products, and promote the balanced development of industrial supply and demand.
(Source: Pharmaceutical Economics News)
